Literature DB >> 21218126

Use of spectral domain-optical coherence tomography to visualize photoreceptor abnormalities in cone-rod dystrophy 6.

Ben J Kim1, Mohamed A Ibrahim, Morton F Goldberg.   

Abstract

PURPOSE: The purpose of this study was to describe the spectral domain-optical coherence tomography findings in a patient with cone-rod dystrophy 6.
METHODS: This is a case report of a 13-year-old girl who presented with progressive loss of vision. Fundus photography, a fluorescein angiogram, an electroretinogram, autofluorescence imaging, spectral domain-optical coherence tomography, and genetic testing were performed.
RESULTS: The patient's fundi showed mild granularity of the perifoveal retinal pigment epithelium. An electroretinogram showed cone dysfunction and normal rod function. Genetic testing showed a heterozygous CGC>CAC nucleotide substitution at codon 838 of the GUCY2D gene. This results in an amino acid change of Arg838His and provides a molecular diagnosis of cone-rod dystrophy 6. The spectral domain-optical coherence tomography showed abnormalities at the inner segment/outer segment junction and the outer segment layer suggestive of loss or disease of photoreceptor outer segments. Autofluorescence imaging showed a perifoveal ring of hyperfluorescence that correlated with abnormallities on spectral domain-optical coherence tomography.
CONCLUSION: Spectral domain-optical coherence tomography can show photoreceptor abnormalities that correlate with the perifoveal ring seen with autofluorescence imaging of patients with cone-rod dystrophy 6. Spectral domain-optical coherence tomography has significant potential for understanding and following the natural history of diseases such as cone-rod dystrophy 6.

Entities:  

Year:  2011        PMID: 21218126      PMCID: PMC3015235          DOI: 10.1097/ICB.0b013e3181cd1d8b

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  9 in total

1.  Codons 837 and 838 in the retinal guanylate cyclase gene on chromosome 17p: hot spots for mutations in autosomal dominant cone-rod dystrophy?

Authors:  M Weigell-Weber; S Fokstuen; B Török; G Niemeyer; A Schinzel; M Hergersberg
Journal:  Arch Ophthalmol       Date:  2000-02

2.  High-definition optical coherence tomographic visualization of photoreceptor layer and retinal flecks in fundus albipunctatus associated with cone dystrophy.

Authors:  Giuseppe Querques; Pascal Carrillo; Lea Querques; Anna V Bux; Maria V Del Curatolo; Nicola Delle Noci
Journal:  Arch Ophthalmol       Date:  2009-05

3.  Autosomal dominant cone-rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase.

Authors:  K Gregory-Evans; R E Kelsell; C Y Gregory-Evans; S M Downes; F W Fitzke; G E Holder; M Simunovic; J D Mollon; R Taylor; D M Hunt; A C Bird; A T Moore
Journal:  Ophthalmology       Date:  2000-01       Impact factor: 12.079

4.  Functional characterization of missense mutations at codon 838 in retinal guanylate cyclase correlates with disease severity in patients with autosomal dominant cone-rod dystrophy.

Authors:  S E Wilkie; R J Newbold; E Deery; C E Walker; I Stinton; V Ramamurthy; J B Hurley; S S Bhattacharya; M J Warren; D M Hunt
Journal:  Hum Mol Genet       Date:  2000-12-12       Impact factor: 6.150

5.  Autosomal dominant cone-rod dystrophy with mutations in the guanylate cyclase 2D gene encoding retinal guanylate cyclase-1.

Authors:  S M Downes; A M Payne; R E Kelsell; F W Fitzke; G E Holder; D M Hunt; A T Moore; A C Bird
Journal:  Arch Ophthalmol       Date:  2001-11

6.  Histopathologic and immunohistochemical study of dominant cone degeneration.

Authors:  K To; M Adamian; F A Jakobiec; E L Berson
Journal:  Am J Ophthalmol       Date:  1998-07       Impact factor: 5.258

7.  Abnormal cone synapses in human cone-rod dystrophy.

Authors:  K Gregory-Evans; R N Fariss; D E Possin; C Y Gregory-Evans; A H Milam
Journal:  Ophthalmology       Date:  1998-12       Impact factor: 12.079

8.  Functional correlates of fundus autofluorescence abnormalities in patients with RPGR or RIMS1 mutations causing cone or cone rod dystrophy.

Authors:  A G Robson; M Michaelides; V A Luong; G E Holder; A C Bird; A R Webster; A T Moore; F W Fitzke
Journal:  Br J Ophthalmol       Date:  2007-10-25       Impact factor: 4.638

9.  Structural assessment of hyperautofluorescent ring in patients with retinitis pigmentosa.

Authors:  Luiz H Lima; Wener Cella; Vivienne C Greenstein; Nan-Kai Wang; Mihai Busuioc; R Theodore Smith; Lawrence A Yannuzzi; Stephen H Tsang
Journal:  Retina       Date:  2009 Jul-Aug       Impact factor: 4.256

  9 in total
  5 in total

1.  Morphologic characteristics of the outer retina in cone dystrophy on spectral-domain optical coherence tomography.

Authors:  Soo Chang Cho; Se Joon Woo; Kyu Hyung Park; Jeong-Min Hwang
Journal:  Korean J Ophthalmol       Date:  2013-01-15

2.  A recurrent mutation in GUCY2D associated with autosomal dominant cone dystrophy in a Chinese family.

Authors:  Xueshan Xiao; Xiangming Guo; Xiaoyun Jia; Shiqiang Li; Panfeng Wang; Qingjiong Zhang
Journal:  Mol Vis       Date:  2011-12-15       Impact factor: 2.367

3.  A case of anterior persistent hyperplastic primary vitreous associated with morning glory disc anomaly and retinopathy of prematurity like retinopathy in a term-born child.

Authors:  Hao Zhang; Kaiqin She; Fang Lu
Journal:  BMC Ophthalmol       Date:  2021-12-28       Impact factor: 2.209

4.  GUCY2D-Related Retinal Dystrophy with Autosomal Dominant Inheritance-A Multicenter Case Series and Review of Reported Data.

Authors:  Jonas Neubauer; Leo Hahn; Johannes Birtel; Camiel J F Boon; Peter Charbel Issa; M Dominik Fischer
Journal:  Genes (Basel)       Date:  2022-02-08       Impact factor: 4.096

5.  Rapid cohort generation and analysis of disease spectrum of large animal model of cone dystrophy.

Authors:  Corinne Kostic; Simon Geoffrey Lillico; Sylvain Vincent Crippa; Nicolas Grandchamp; Héloïse Pilet; Stéphanie Philippe; Zen Lu; Tim James King; Jacques Mallet; Chamsy Sarkis; Yvan Arsenijevic; Christopher Bruce Alexander Whitelaw
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.